The use of a CD93 monoclonal antibody was shown to promote vascular maturation, alleviate tumor hypoxia, and increase tumor perfusion without significantly affecting vascular homeostasis in healthy organs, unlike anti-VEGFR monoclonal antibodies. The gene discussed is KDR; the disease is neoplasm.